Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.50 |
| ▸ | LSS | P48449 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | ADH5 | P11766 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104338 | 0.78 | LSS (0.52) | LSSKMT2ACYP3A4BAZ2BHTR2A | |
| SCHEMBL762618 | 0.76 | MCHR2 (0.58) | MCHR2NPC1L1HSD11B1FFAR1NR1H2 | |
| SCHEMBL4984631 | 0.76 | MCHR2 (0.60) | MCHR2KMT2ANPC1L1HSD11B1FFAR1 | |
| SCHEMBL739407 | 0.75 | MCHR2 (0.50) | MCHR2KMT2ANPC1L1HSD11B1FFAR1 | |
| SCHEMBL3839355 | 0.74 | MCHR2 (0.61) | MCHR2NPC1L1HSD11B1FFAR1HTT | |
| SCHEMBL3837633 | 0.73 | MCHR2 (0.60) | MCHR2KMT2ANPC1L1HSD11B1 | |
| SCHEMBL395086 | 0.73 | HSD11B1 (0.64) | MCHR2NPC1L1HSD11B1NR1H2NR1H3 | |
| SCHEMBL9363641 | 0.72 | HPGD (0.68) | LSSKMT2ACYP3A4BAZ2BHTR2A | |
| SCHEMBL8536306 | 0.72 | LSS (0.60) | LSSCYP3A4BAZ2BHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL9368954 | 0.71 | HPGD (0.66) | LSSKMT2ACYP3A4BAZ2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105289-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | claimed |
| EP-1802623-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS | Novo Nordisk A/S (DK) | 2007-07-04 | — | — | EP | claimed |
| WO-2006040329-A1 | 1 IBETA- HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-04-20 | — | — | WO | claimed |
| US-8138342-B2 | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds | High Point Pharmacueticals, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138342-B2 | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds | High Point Pharmacueticals, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138342-B2 | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds | High Point Pharmacueticals, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090105289-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105289-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105289-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-1802623-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS | Novo Nordisk A/S (DK) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040329-A1 | 1 IBETA- HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105289-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds | HSD11B1, HSD3B1, HSD17B1 | MCHR2 3967/4885LSS 90/4885KMT2A 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.